Journal of Clinical Oncology
Articles in this Issue
Prognostic performance of Child-Pugh and MELD scores in critically ill patients with hepatocellular carcinoma: A MIMIC-IV cohort study.
e16235 Background: Hepatocellular carcinoma predominantly arises in cirrhotic patients, creating dual disease burd...
Clinical characteristics of patients with metastatic uveal melanoma and assessment of long-term survivors.
e21509 Background: Metastatic uveal melanoma (MUM) is a rare malignancy with poor prognosis and limited systemic treatment...
Dermatologic adverse events (dAEs) and emotional quality of life (QoL) in patients (pts) with breast cancer: A mixed-methods study.
12076 Background: dAEs are a common and impactful aspect of QoL and have an emotional impact. However, its measurement rel...
Real-world outcomes in <i>EGFR</i> subtypes and co- <i>TP53</i> mutations in metastatic non-small cell lung cancer.
e20705 Background: EGFR mutations are key oncogenic drivers in non–small cell lung cancer (NSCLC) and...
Malignant pericardial effusion: A high-risk marker for in-hospital mortality and cardiovascular collapse in cancer patients.
e24032 Background: Malignant pericardial effusion (MPE) is a known complication of advanced malignancy and may reflect agg...
Real-world data from the TriNetX database comparing abiraterone versus darolutamide in hormone-sensitive prostate cancer.
e17092 Background: Abiraterone and darolutamide are among several novel androgen receptor pathway inhibitors (ARPIs) that...
Impact of inulin on immunotherapy efficacy in extensive-stage small cell lung cancer and on promotion of CD8+ T-cell tumor infiltration and functional activity.
e20145 Background: Response to immune checkpoint inhibitor (ICI)–based therapy in extensive-stage small cell lung cancer (...
A multi-axis biomarker model integrating KIM-1 and MAdCAM-1 in metastatic renal cell carcinoma.
4554 Background: Kidney injury molecule-1 (KIM-1) and mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1) have...
Clinicopathological characteristics, treatment patterns, and contrast-enhanced computed tomography surveillance in post-treated breast cancer patients: A single-center study from Nepal.
e13626 Background: Breast cancer is a leading malignancy in Nepal. While mammography is the surveillance standard, its sen...
Artificial intelligence (AI) in hematology and oncology fellowship (HOF) training: A multicenter survey of education, attitudes, and clinical use.
9001 Background: A prior national survey of U.S. HOF curricula demonstrated substantial heterogeneity and limited protecte...
One vs. 2 vs. ≥3 <i>TET2</i> mutations in chronic myelomonocytic leukemia: Co-mutation patterns and prognostic correlates.
6588 Background: TET2 is the most frequently mutated gene in chronic myelomonocytic leukemia (CMML) an...
Alpha-emitting radionuclide or beta-emitting radionuclide combined with metastasis-directed stereotactic body radiotherapy for oligorecurrent prostate adenocarcinoma (ANDROMEDA): A phase II trial.
TPS3175 Background: The recent LUNAR study (NCT05496959) found that adding beta-emitting 177...
Prevalence and regional variation of cervical cancer in Nigeria: A systematic review and meta-analysis (2010–2025).
e17519 Background: Cervical cancer remains a leading cause of cancer-related morbidity and mortality among women in low- a...
Dyadic exercise intervention for LGBTQ+ cancer survivors: Associations with health-related quality of life, fatigue, and inflammation biomarkers.
12041 Background: Mixed training (aerobic/resistance) exercise is a key adjuvant therapy in exercise oncology; it decrease...
Characterization of tumor immune microenvironment and real-world efficacy of first-line immunotherapy in <i>BRAF</i> -mutant non–small cell lung cancer.
e20607 Background: The efficacy of immune checkpoint inhibitors (ICIs) in BRAF-mutant non-small cell lung cancer (NSCLC) r...
The CONVERGE study: A phase II, single-arm trial of adebelimab combined with targeted therapy and liposomal irinotecan-based chemotherapy for conversion surgery in unresectable MSS colorectal cancer liver metastases.
3604 Background: Liver metastasis is a key poor prognostic factor for colorectal cancer (CRC). Microsatellite stable (MSS)...
Cost-effectiveness analysis of teclistamab plus daratumumab in relapsed or refractory multiple myeloma.
11038 Background: Relapsed or refractory multiple myeloma (RRMM) remains a significant therapeutic and economic challenge...
Neoadjuvant chemokine modulation of the tumor microenvironment (TME) in resectable metastatic colorectal cancer: Results from a phase I study.
2606 Background: Our preclinical studies using ex vivo explant cultures of resected metastatic colorectal cancer (CRC) tis...
A novel rapid Th9/Tc9-polarized CAR-T manufacturing platform to enable metabolic fitness and superior antitumor potency in solid tumors.
e14501 Background: The efficacy of CAR-T therapy in solid tumors is hindered by poor T-cell fitness and rapid exha...
KEYMAKER-U01J: Calderasib plus pembrolizumab with or without cetuximab as first-line treatment for advanced or metastatic nonsquamous non–small-cell lung cancer (NSCLC) with <i>KRAS</i> G12C mutations.
TPS8679 Background: The anti–PD-1 pembrolizumab (pembro) + chemotherapy (chemo) is a standard of care first-line therapy f...
Hetrombopag plus caffeic acid tablets for the treatment of chemotherapy-induced thrombocytopenia in solid tumors: A single-center, open-label, phase II trial.
12130 Background: Chemotherapy-induced thrombocytopenia (CIT) frequently complicates cancer therapy, resulting in treatmen...
Total tumor burden: An automated estimate of scan-level volumetric lung tumor burden from routine CT.
e15012 Background: In clinical trials, tumor burden and treatment response are routinely estimated by applying RECIST 1.1...
Dinutuximab beta in combination with chemotherapy in patients with refractory or relapsed neuroblastoma: A national prospective study (2020/ABM/01/00055).
10037 Background: The ChIm-NB-PL phase IIa trial (EudraCT: 2021-003832-96) evaluated the safety and efficacy of dinutuxima...
Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY-Breast07.
1012 Background: T-DXd is approved for adult pts with HER2+ mBC who received a prior anti-HER2–based regimen, or as 1L the...
First-in-human phase I/II study of MRG006A, a first-in-class Glypican-3 (GPC3)–targeted antibody-drug conjugate (ADC), in patients (pts) with advanced hepatocellular carcinoma (HCC).
3028 Background: Pts with advanced HCC face limited treatment options beyond immunotherapy and anti-angiogenic agents. GPC...